News
EMI
5.00
0.00%
0.00
Emperador’s Public Float at 25.43% as Alliance Global Holds Majority Stake
TipRanks · 10/16 03:57
Emperador Updates Top Shareholders and Capital Structure Data
TipRanks · 10/16 03:57
Emperador Settles Part of ELS Shares in Cash, Leaves Remainder Convertible
TipRanks · 08/24 02:22
Emperador Rejoins FTSE Global Equity Index, Boosting Investor Visibility
TipRanks · 08/24 02:22
Emperador Extends Conversion Period for Arran Equity-Linked Shares
TipRanks · 08/12 07:10
Emperador Updates Governance, Confirms Concentrated Ownership in SEC Filing
TipRanks · 07/22 04:22
Emperador’s June Public Ownership Report Confirms 25% Free Float and Majority Control by Alliance Global
TipRanks · 07/15 03:32
Emperador Earmarks Php 2.4 Billion Capex for 2026 After Major Expansion Drive
TipRanks · 06/24 05:53
Emperador Stockholders Ratify Board, Governance Actions at 2026 Annual Meeting
TipRanks · 06/24 03:42
Emperador Revamps Board Leadership and Bolsters Governance Committees
TipRanks · 06/24 03:42
Emperador to Settle ₱1-Million SEC Assessment Over 2023 Financial Statement Issue
TipRanks · 06/05 08:54
Emperador details full compliance in 2025 corporate governance report
TipRanks · 05/29 08:48
Q1 Earnings Kick Off With Major Banks' Results: Bank of America, Netflix In Focus
Seeking Alpha · 04/11 15:00
Catalyst Watch: Earnings heat up, Fedspeak flurry, and eyes on space
Seeking Alpha · 04/10 19:00
More
Webull provides a variety of real-time EMI stock news. You can receive the latest news about Encore Medical, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About EMI
Encore Medical, Inc. develops, manufactures, and markets septal occlusion devices for the repair of certain cardiac defects. The Company’s septal occlusion devices are small, implantable devices that are positioned and delivered through a catheter inserted into a major blood vessel (typically via femoral venous access) to repair certain cardiac defects in both adults and children. These closure devices are capable of providing an effective, nonsurgical method of correcting a variety of cardiac defects. Its primary closure device is designed to correct a cardiac defect, generally diagnosed in adulthood, known as a patent foramen ovale (PFO).The PFO defect is an abnormal passage or flap-like hole between the atrial chambers of the heart that can enable embolic material (clots) to travel from the right to left chambers and potentially cause a stroke. It also markets and sells septal occlusion devices for the transcatheter closure of atrial septal defects (ASD).